Mineralys Therapeutics entered into an underwriting agreement on June 3, 2026 to sell 5,660,378 shares of common stock through BofA Securities, Goldman Sachs, and Evercore. The offering follows an effective shelf registration statement and represents a capital raise for the clinical-stage therapeutics company.